SLC5A2 and metabolic disease: Additionally, research on SGLT-2 inhibitor drugs shows that they exert anti-tumor effects by modulating the AMPK/mTOR and HIF-1α pathways [69], providing a new perspective on the overlap between pathways in metabolic diseases and cancer.